Unmasking BACE1 and Age-related Diseases
BACE1 plays a key role in the amyloidogenic process (see Glossary), and its neuronal functions have been studied extensively[1]. Since 2000, intense efforts have been focused on developing small molecule BACE1 inhibitors to reduce the production of amyloid (Ab) in Alzheimer’s (AD) brains. Human clinical trials of most BACE1 inhibiters were stopped in Phase 2/3 because the therapeutic benefits were limited[2]. BACE1 inhibitors reduce Ab-related brain pathologies. They are therefore used to treat symptoms, rather than the disease itself.
Source:
https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(22)00312-4
